Y-Biologics CEO Jang Woo-ik Exercises 60,000 Stock Options, Slightly Increasing Stake

Y-Biologics CEO Jang Woo-ik exercised 60,000 stock options on April 9, 2026, acquiring 60,000 common shares.
The exercise price was 9,767 KRW per share, totaling approximately 586 million KRW, which is 0.15% of the market cap of 391.6 billion KRW.
This increases his stake to 0.39%, but the new shares represent only 0.39% of total outstanding shares, resulting in minimal dilution for existing shareholders.
The stock option exercise is a routine executive compensation event with no capital raising or growth purpose.
The counterparty is the CEO as an individual, posing no governance concerns.
[AI Summary]The CEO's stock option exercise is a minor equity increase with neutral impact on shareholder value. With a dilution of only 0.39% and no capital allocation for growth, this event is not material for investors.